ProQR Therapeutics N.V.
Stock Forecast, Prediction & Price Target
ProQR Therapeutics N.V. Financial Estimates
ProQR Therapeutics N.V. Revenue Estimates
ProQR Therapeutics N.V. EBITDA Estimates
ProQR Therapeutics N.V. Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $1.35M N/A | $4.03M 198.15% | $6.51M 61.35% | Avg: $16.79M Low: $6.28M High: $33.54M avg. 157.77% | Avg: $12.14M Low: $4.05M High: $23.92M avg. -27.69% | Avg: $11.60M Low: $3.87M High: $22.86M avg. -4.42% | Avg: $68.92M Low: $22.99M High: $135.81M avg. 493.98% |
Net Income
% change YoY
| $-61.68M N/A | $-64.89M -5.20% | $-28.11M 56.66% | Avg: $-31.30M Low: $-39.18M High: $-20.36M avg. -11.32% | Avg: $-45.04M Low: $-42.19M High: $-28.33M avg. -43.89% | Avg: $-41.04M Low: $-92.83M High: $-5.48M avg. 8.87% | Avg: $-10.85M Low: $-24.54M High: $-1.45M avg. 73.55% |
EBITDA
% change YoY
| $-55.37M N/A | $-59.38M -7.23% | $-24.09M 59.42% | Avg: $-10.07M Low: $-20.12M High: $-3.77M avg. 58.18% | Avg: $-7.28M Low: $-14.35M High: $-2.43M avg. 27.69% | Avg: $-6.96M Low: $-13.71M High: $-2.32M avg. 4.42% | Avg: $-41.35M Low: $-81.48M High: $-13.79M avg. -493.98% |
EPS
% change YoY
| -$0.96 N/A | -$0.91 5.20% | -$0.35 61.53% | Avg: -$0.39 Low: -$0.48 High: -$0.25 avg. -10.12% | Avg: -$0.41 Low: -$0.52 High: -$0.35 avg. -7.41% | Avg: -$0.51 Low: -$1.15 High: -$0.07 avg. -22.39% | Avg: -$0.13 Low: -$0.3 High: -$0.02 avg. 73.55% |
Operating Expenses
% change YoY
| $58.54M N/A | $68.75M 17.43% | $38.37M -44.18% | Avg: $92.44M Low: $34.59M High: $184.68M avg. 140.91% | Avg: $66.84M Low: $22.30M High: $131.70M avg. -27.69% | Avg: $63.88M Low: $21.31M High: $125.88M avg. -4.42% | Avg: $379.47M Low: $126.60M High: $747.71M avg. 493.98% |
FAQ
What is ProQR Therapeutics N.V. stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 6.80% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -39.18M, average is -31.30M and high is -20.36M.
What is ProQR Therapeutics N.V. stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 154.91% in 2025-2028.
We have gathered data from 3 analysts. Their low revenue estimate is $6.28M, average is $16.79M and high is $33.54M.
What is ProQR Therapeutics N.V. stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 8.40% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$0.48, average is -$0.39 and high is $-0.25.
What is the best performing analyst?
In the last twelve months analysts have been covering ProQR Therapeutics N.V. stock. The most successful analyst is Keay Nakae.